Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Immunology

Abstract #1235: EPI0030, a humanized anti-VEGF rabbit monoclonal antibody, exhibits potent activity in preclinical models

Yongke Zhang, Yaohuang Ke, Pierre Lee, Qiu Yu, Weimin Zhu and Guo-Liang Yu
Yongke Zhang
Epitomics, Inc., Burlingame, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yaohuang Ke
Epitomics, Inc., Burlingame, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pierre Lee
Epitomics, Inc., Burlingame, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qiu Yu
Epitomics, Inc., Burlingame, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Weimin Zhu
Epitomics, Inc., Burlingame, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guo-Liang Yu
Epitomics, Inc., Burlingame, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2009
  • Article
  • Info & Metrics
Loading
AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

Abstract

Tumor growth and development is dependent on the formation of a neovasculature. Vascular endothelial growth factor-A (VEGF-A) play a key role in the vascular development of tumors. Finding new and effective therapies targeting tumor angiogenesis represents an unmet need. Here we present the generation and characterization of a novel humanized anti-VEGF rabbit monoclonal antibody, EPI0030, which was generated using Epitomics\#8217;s robust RabMab\#8482; platform and our proprietary Mutational-Lineage-Guided (MLG)-drived humanization technology. EPI0030 selectively blocks VEGF-A binding to VEGFR2, the receptor primarily responsible for tumor angiogenesis. This antibody is characterized and compared with marketed anti-cancer agent Avastin by: i) increased affinity for VEGF-A, ii) improved blocking of VEGF binding to VEGFR and its signal transduction, and iii) significantly increase in in vivo antitumor potency. In an established preclinical NCI-H460 lung cancer model, EPI0030 reduced the growth of the tumors by 86% with a concomitant decrease in microvessel density, while Avastin only moderately inhibited the tumor growth by 37%. The anti-tumor activity of EPI0030 compared favorably to that of Avastin, supporting that selective blocking of VEGF binding to VEGFR2 by EPI0030 may ultimately offer safety or efficacy benefits over current marketed cancer drugs. Additional preclinical studies are planned to evaluate EPI0030 as a potential clinical candidate based on its anti-tumor activity.

Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 1235.

Footnotes

  • 100th AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

  • American Association for Cancer Research
Back to top
Cancer Research: 69 (9 Supplement)
May 2009
Volume 69, Issue 9 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract #1235: EPI0030, a humanized anti-VEGF rabbit monoclonal antibody, exhibits potent activity in preclinical models
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract #1235: EPI0030, a humanized anti-VEGF rabbit monoclonal antibody, exhibits potent activity in preclinical models
Yongke Zhang, Yaohuang Ke, Pierre Lee, Qiu Yu, Weimin Zhu and Guo-Liang Yu
Cancer Res May 1 2009 (69) (9 Supplement) 1235;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract #1235: EPI0030, a humanized anti-VEGF rabbit monoclonal antibody, exhibits potent activity in preclinical models
Yongke Zhang, Yaohuang Ke, Pierre Lee, Qiu Yu, Weimin Zhu and Guo-Liang Yu
Cancer Res May 1 2009 (69) (9 Supplement) 1235;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Immunology

  • Abstract SY03-03: Modulating innate and adaptive immunity through the manipulation of dendritic cells
  • Abstract SY03-02: Wnt signaling generates “stem-like” self-renewing T cells that can eradicate tumors
  • Abstract SY03-01: The desirable death of the cancer cell: Immunogenic cell death for optimal chemotherapy
Show more 3

Antibody and Antibody Targets -- Poster Presentations - Proffered Abstracts

  • Abstract #1237: Preclinical pharmacokinetic and pharmacodynamic data for TRC105 (anti-endoglin antibody) are consistent with clinical activity observed at low doses in patients with advanced cancer
  • Abstract #1238: Monoclonal antibodies to desmoglein 3 exhibit in vivo anti-tumor efficacy
  • Abstract #1243: In vivo effect of combination therapy: An anti ErbB3 antibody, MM121, plus selected cancer therapies
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement